Zhongyun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhongyun Chen has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Liyong Wu
Department of Neurology, Xuanwu Hospital Capital Medical University Beijing China
12 shared publications - Kexin Xie
Xuanwu Hospital, Capital Medical University, Beijing China
6 shared publications - Yu Kong
Department of neurology, XuanWu hospital, capital medical university, Beijing China
4 shared publications - Yue Cui
Xuanwu Hospital, Capital Medical University, Beijing China
4 shared publications Jing Zhang
Department of Neurology, Xuanwu Hospital Capital Medical University Beijing China
3 shared publications- Jing Zhang
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
3 shared publications
Latest Publications
- 27 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 657
E200K genetic Creutzfeldt–Jakob disease with codon 129 MV heterozygosity presenting with a V2-like phenotype: a case report
- 27 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 657
E200K genetic Creutzfeldt–Jakob disease with codon 129 MV heterozygosity presenting with a V2-like phenotype: a case report
- 31 January 2026
- Published by MyJove Corporation
JoVE Video Dataset
- 30 January 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 227,p. e69710
Nutritional Risk Assessment and Its Prognostic Impact in Critically Ill Patients with Neurological Diseases
The research aims to apply and evaluate a standardized protocol for nutritional risk assessment and nutritional support management, and to assess its predictive value in individuals with severe neurological disorders who are at risk of malnutrition. A retrospective analysis was performed on 930 suitable patients hospitalized in the Neurology Intensive Care Unit (NICU) at Xuanwu Hospital, Capital Medical University, between January 2012 and December 2019. At discharge, patients were categorized based on modified Rankin Scale (mRS) results (excellent prognosis: mRS 0-2, n = 600; bad prognosis: mRS 3-6, n = 330) and survival status (survivor: n = 869; deceased: n = 61). The protocol included baseline characteristics and biochemical evaluations, admission Nutritional Risk Screening 2002 (NRS 2002) scores, identifying the nutritional support modality, estimation of typical energy intake throughout the first 7 days, and level of disease evaluation using standardized assessment instruments such as the Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE II), and National Institutes of Health Stroke Scale (NIHSS). Univariate studies, multivariate logistic regression estimation, and receiver operating characteristic (ROC) curve assessment were used to assess predictive significance. The standardized protocol enabled the systematic identification of nutritional risk, stratification of clinical severity, and early guidance for planning nutritional interventions. Key risk indicators, including elevated NRS 2002, APACHE II, and NIHSS scores, advanced age, and inadequate early energy intake, were associated with unfavorable outcomes. In contrast, higher GCS and adequate vitamin B12 levels demonstrated protective tendencies. ROC analysis confirmed that NRS 2002 provided the most effective predictive utility for both functional outcome and survival status. The findings demonstrate that structured nutritional risk assessment and standardized support implementation offer practical value for early prognostic judgment and Nutritional decision-making for severely ill individuals suffering from neurological diseases.
- 30 January 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 227,p. e69710
Nutritional Risk Assessment and Its Prognostic Impact in Critically Ill Patients with Neurological Diseases
The research aims to apply and evaluate a standardized protocol for nutritional risk assessment and nutritional support management, and to assess its predictive value in individuals with severe neurological disorders who are at risk of malnutrition. A retrospective analysis was performed on 930 suitable patients hospitalized in the Neurology Intensive Care Unit (NICU) at Xuanwu Hospital, Capital Medical University, between January 2012 and December 2019. At discharge, patients were categorized based on modified Rankin Scale (mRS) results (excellent prognosis: mRS 0-2, n = 600; bad prognosis: mRS 3-6, n = 330) and survival status (survivor: n = 869; deceased: n = 61). The protocol included baseline characteristics and biochemical evaluations, admission Nutritional Risk Screening 2002 (NRS 2002) scores, identifying the nutritional support modality, estimation of typical energy intake throughout the first 7 days, and level of disease evaluation using standardized assessment instruments such as the Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE II), and National Institutes of Health Stroke Scale (NIHSS). Univariate studies, multivariate logistic regression estimation, and receiver operating characteristic (ROC) curve assessment were used to assess predictive significance. The standardized protocol enabled the systematic identification of nutritional risk, stratification of clinical severity, and early guidance for planning nutritional interventions. Key risk indicators, including elevated NRS 2002, APACHE II, and NIHSS scores, advanced age, and inadequate early energy intake, were associated with unfavorable outcomes. In contrast, higher GCS and adequate vitamin B12 levels demonstrated protective tendencies. ROC analysis confirmed that NRS 2002 provided the most effective predictive utility for both functional outcome and survival status. The findings demonstrate that structured nutritional risk assessment and standardized support implementation offer practical value for early prognostic judgment and Nutritional decision-making for severely ill individuals suffering from neurological diseases.
- Open Access
- 23 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70765
Peripheral Signatures of Multidimensional Pathology in Symptomatic and Asymptomatic Creutzfeldt–Jakob Disease
Background: Plasma markers of neuronal injury in Creutzfeldt–Jakob disease (CJD) are established, but peripheral biomarkers reflecting glial activation, synaptic dysfunction, and vascular impairment remain less explored. We systematically assessed these markers in symptomatic CJD and asymptomatic PRNP mutation carriers to improve diagnosis and identify early pathophysiology. Methods: This prospective cohort study recruited CJD, frontotemporal dementia (FTD), healthy controls (HCs), and preclinical familial CJD pedigrees. Sixteen plasma proteins representing neuronal injury, glial activation, synaptic function, and vascular/BBB integrity were measured. Analyses included group differences, discriminative performance, clinical/imaging correlations, and longitudinal trajectories. Results: We enrolled 130 CJD patients, 145 FTD, 70 HCs, 16 asymptomatic PRNP carriers (4–6 years follow‐up, 4 converters), and 16 non‐carrier family controls. In symptomatic CJD, plasma NfL, t‐tau, and GFAP were strongly elevated, each showing excellent discriminative performance (AUCs > 0.93 vs. HCs and > 0.82 vs. FTD). We also observed alterations in vascular/BBB markers, with VCAM‐1 levels elevated and significantly associated with both clinical decline and DWI hyperintensity. In asymptomatic carriers, biomarker levels remained largely normal and stable preclinically. Notably, two G114V carriers showed mild pre‐symptomatic elevations in NfL and GFAP, and one exhibited a slight VCAM‐1 increase before clinical onset; all changes exceeded the 90th percentile of control values. E200K and T188K carriers showed no pre‐onset changes. Conclusions: Plasma biomarkers in CJD may reflect multisystem involvement, with neuronal markers showing strong discriminative potential and vascular proteins indicating possible BBB dysfunction. In asymptomatic carriers, minor changes may occur only near onset in those with relatively slow‐progressing mutations.
- 23 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70765
Open AccessPeripheral Signatures of Multidimensional Pathology in Symptomatic and Asymptomatic Creutzfeldt–Jakob Disease
Background: Plasma markers of neuronal injury in Creutzfeldt–Jakob disease (CJD) are established, but peripheral biomarkers reflecting glial activation, synaptic dysfunction, and vascular impairment remain less explored. We systematically assessed these markers in symptomatic CJD and asymptomatic PRNP mutation carriers to improve diagnosis and identify early pathophysiology. Methods: This prospective cohort study recruited CJD, frontotemporal dementia (FTD), healthy controls (HCs), and preclinical familial CJD pedigrees. Sixteen plasma proteins representing neuronal injury, glial activation, synaptic function, and vascular/BBB integrity were measured. Analyses included group differences, discriminative performance, clinical/imaging correlations, and longitudinal trajectories. Results: We enrolled 130 CJD patients, 145 FTD, 70 HCs, 16 asymptomatic PRNP carriers (4–6 years follow‐up, 4 converters), and 16 non‐carrier family controls. In symptomatic CJD, plasma NfL, t‐tau, and GFAP were strongly elevated, each showing excellent discriminative performance (AUCs > 0.93 vs. HCs and > 0.82 vs. FTD). We also observed alterations in vascular/BBB markers, with VCAM‐1 levels elevated and significantly associated with both clinical decline and DWI hyperintensity. In asymptomatic carriers, biomarker levels remained largely normal and stable preclinically. Notably, two G114V carriers showed mild pre‐symptomatic elevations in NfL and GFAP, and one exhibited a slight VCAM‐1 increase before clinical onset; all changes exceeded the 90th percentile of control values. E200K and T188K carriers showed no pre‐onset changes. Conclusions: Plasma biomarkers in CJD may reflect multisystem involvement, with neuronal markers showing strong discriminative potential and vascular proteins indicating possible BBB dysfunction. In asymptomatic carriers, minor changes may occur only near onset in those with relatively slow‐progressing mutations.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214297
Clinical Reasoning: A 10-Year-Old Boy With Progressive Tremor, Insomnia, and Autonomic Dysfunction
A 10-year-old boy developed progressive tremor, insomnia, and autonomic dysfunction after an upper respiratory tract infection. Initial workup, including brain MRI, CSF analysis, and antibody screening, was unremarkable. By the third month of illness, brain MRI revealed multiple hyperintensities on fluid-attenuated inversion recovery sequences. Empiric immunotherapy led to partial clinical and radiologic improvement. However, neurologic deterioration continued despite subsequent immunosuppressive treatment, and follow-up imaging demonstrated progressive cerebral atrophy. 18F-fluorodeoxyglucose PET revealed marked bilateral thalamic hypometabolism, providing a pivotal clue that redirected the diagnostic approach. Definitive diagnosis was ultimately established through targeted genetic analysis. This case underscores the importance of maintaining a broad differential diagnosis in pediatric patients presenting with progressive neurologic decline, even in the context of transient inflammatory or immune-appearing features. It also highlights the diagnostic value of genetic testing when conventional investigations are inconclusive.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214297
Clinical Reasoning: A 10-Year-Old Boy With Progressive Tremor, Insomnia, and Autonomic Dysfunction
A 10-year-old boy developed progressive tremor, insomnia, and autonomic dysfunction after an upper respiratory tract infection. Initial workup, including brain MRI, CSF analysis, and antibody screening, was unremarkable. By the third month of illness, brain MRI revealed multiple hyperintensities on fluid-attenuated inversion recovery sequences. Empiric immunotherapy led to partial clinical and radiologic improvement. However, neurologic deterioration continued despite subsequent immunosuppressive treatment, and follow-up imaging demonstrated progressive cerebral atrophy. 18F-fluorodeoxyglucose PET revealed marked bilateral thalamic hypometabolism, providing a pivotal clue that redirected the diagnostic approach. Definitive diagnosis was ultimately established through targeted genetic analysis. This case underscores the importance of maintaining a broad differential diagnosis in pediatric patients presenting with progressive neurologic decline, even in the context of transient inflammatory or immune-appearing features. It also highlights the diagnostic value of genetic testing when conventional investigations are inconclusive.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Application of the mild behavioral impairment checklist in Chinese patients with the behavioral variant of frontotemporal dementia
Background: The mild behavioral impairment checklist (MBI‐C) designed to capture neuropsychiatric symptoms in the whole spectrum of elder with or without dementia, have been verified in mild behavioral impairment, mild cognitive impairment and Alzheimer’s Disease, but never used in the behavioral variant of frontotemporal dementia (bvFTD).Method: Fifty‐two patients with bvFTD (mild, n = 30; moderate‐severe, n = 22) and 82 community‐dwelling elderly individuals (HCs) were enrolled. All subjects were assessed with a full neuropsychological scale including the MBI‐C, Neuropsychiatric Inventory Questionnaire (NPI‐Q), and Frontal Behavioral Inventory (FBI). Receiver operating characteristic curves were drawn to analyze the sensitivity and specificity of the MBI‐C, NPI‐Q, and FBI, and cutoff points were determined using the Youden index.Result: The MBI‐C and domain scores in all patients with bvFTD were significantly higher than those in HCs. The most common symptoms of bvFTD were apathy (82.7%) and impulse dyscontrol (80.8%). The MBI‐C score was positively correlated with the NPI‐Q, FBI, and Activities of Daily Living. For differentiating patients with both bvFTD and mild bvFTD from HCs, the optimal MBI‐C cutoff point was 5/6 with a sensitivity of 100% and specificity of 82%, and its sensitivity was higher than that of the NPI‐Q and FBI.Conclusion: The MBI‐C is a sensitive tool for screening behavioral and psychological symptoms in patients with bvFTD, even in the early stages of the disease.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessApplication of the mild behavioral impairment checklist in Chinese patients with the behavioral variant of frontotemporal dementia
Background: The mild behavioral impairment checklist (MBI‐C) designed to capture neuropsychiatric symptoms in the whole spectrum of elder with or without dementia, have been verified in mild behavioral impairment, mild cognitive impairment and Alzheimer’s Disease, but never used in the behavioral variant of frontotemporal dementia (bvFTD).Method: Fifty‐two patients with bvFTD (mild, n = 30; moderate‐severe, n = 22) and 82 community‐dwelling elderly individuals (HCs) were enrolled. All subjects were assessed with a full neuropsychological scale including the MBI‐C, Neuropsychiatric Inventory Questionnaire (NPI‐Q), and Frontal Behavioral Inventory (FBI). Receiver operating characteristic curves were drawn to analyze the sensitivity and specificity of the MBI‐C, NPI‐Q, and FBI, and cutoff points were determined using the Youden index.Result: The MBI‐C and domain scores in all patients with bvFTD were significantly higher than those in HCs. The most common symptoms of bvFTD were apathy (82.7%) and impulse dyscontrol (80.8%). The MBI‐C score was positively correlated with the NPI‐Q, FBI, and Activities of Daily Living. For differentiating patients with both bvFTD and mild bvFTD from HCs, the optimal MBI‐C cutoff point was 5/6 with a sensitivity of 100% and specificity of 82%, and its sensitivity was higher than that of the NPI‐Q and FBI.Conclusion: The MBI‐C is a sensitive tool for screening behavioral and psychological symptoms in patients with bvFTD, even in the early stages of the disease.
- 26 October 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (3) , 1275-1277
Dynamic diffusion imaging changes and unique midbrain involvement in a probable MV2K sCJD
- 26 October 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (3) , 1275-1277
Dynamic diffusion imaging changes and unique midbrain involvement in a probable MV2K sCJD
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S2)
Erythrocyte indices in creutzfeldt–jakob disease predict survival time
Background: Creutzfeldt–Jakob disease (CJD) is a devastating neurodegenerative disease caused by propagation of abnormally folded prion proteins (PrPSc). Some fluid biomarkers have been reported to be associated with disease duration in CJD. Based on studies which have found that prion protein (PrPC) played a role in erythrocytic hematopoiesis, we evaluated the association between peripheral red blood cell indices and survival time in CJD.Method: We retrospectively collected data on peripheral red blood cell indices, including red blood cell (RBC) count, hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), from 125 CJD patients. Cox proportional hazard models were generated to determine whether red cell indices correlated with survival time of patients with CJD.Result: Of the 125 included participants, 70 (56%) were male, and the mean age at diagnosis (SD) was 60.3 (9.5) years. Hemoglobin levels (hazard ratio 1.710, 95% CI 1.124‐2.600, p = 0.012) and HCT (hazard ratio 1.689, 95% CI 1.112‐2.565, p = 0.014) were significantly associated with survival time after controlling for sex, age, and Barthel Index. Red blood cell count, MCV, MCH, MCHC, and RDW were not associated with survival time before or after adjusting for covariates.Conclusion: Our study found that Hb and HCT were significantly associated with survival time in patients with CJD. These results may inform evaluation of the mechanisms of interaction between prion disease and hematopoiesis, and indicate that Hb and HCT may be potential prognostic biomarkers.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S2)
Open AccessErythrocyte indices in creutzfeldt–jakob disease predict survival time
Background: Creutzfeldt–Jakob disease (CJD) is a devastating neurodegenerative disease caused by propagation of abnormally folded prion proteins (PrPSc). Some fluid biomarkers have been reported to be associated with disease duration in CJD. Based on studies which have found that prion protein (PrPC) played a role in erythrocytic hematopoiesis, we evaluated the association between peripheral red blood cell indices and survival time in CJD.Method: We retrospectively collected data on peripheral red blood cell indices, including red blood cell (RBC) count, hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell distribution width (RDW), from 125 CJD patients. Cox proportional hazard models were generated to determine whether red cell indices correlated with survival time of patients with CJD.Result: Of the 125 included participants, 70 (56%) were male, and the mean age at diagnosis (SD) was 60.3 (9.5) years. Hemoglobin levels (hazard ratio 1.710, 95% CI 1.124‐2.600, p = 0.012) and HCT (hazard ratio 1.689, 95% CI 1.112‐2.565, p = 0.014) were significantly associated with survival time after controlling for sex, age, and Barthel Index. Red blood cell count, MCV, MCH, MCHC, and RDW were not associated with survival time before or after adjusting for covariates.Conclusion: Our study found that Hb and HCT were significantly associated with survival time in patients with CJD. These results may inform evaluation of the mechanisms of interaction between prion disease and hematopoiesis, and indicate that Hb and HCT may be potential prognostic biomarkers.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Thalamic‐insomnia phenotype in genetic E200K Creutzfeldt‐Jakob disease: A PET/MRI study
Background: Insomnia and thalamic involvement are hallmarks of fatal familial insomnia; however, it was occasionally reported that genetic E200K Creutzfeldt‐Jakob disease (CJD) patients had also manifested thalamic‐insomnia phenotype. The study aimed to explore the clinical and neuroimage characteristics of genetic E200K CJD by comprehensive neuroimage analysis.Methods: Six genetic CJD patients carried Glu to Lys change at codon 200 (E200K) mutations on prion protein gene (PRNP), thirteen sporadic CJD (sCJD), and twenty‐two age‐ and sex‐matched normal controls were enrolled in the study. All participants completed hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) examinations. The high signal was visually inspected on diffusion weighted imaging (DWI) sequence. 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and structural images were quantitively analyzed by statistically parameter mapping (SPM). Clinical and image characteristics are compared between genetic E200K CJD patients and sporadic CJD patients.Results: There was no group difference in age (49.0±7.1 versus 55.0±4.9 versus 52.7±7.3, p = 0.193) and gender (3/3 versus 4/9 versus 11/11, p = 0.513) between genetic E200K CJD, sCJD, and normal controls. Insomnia was the main complaint in the genetic E200K CJD patients’ group (4/2 versus 1/12, p = 0.007). Hyperintensity, hypometabolism but not predominant atrophy of the thalamus was found by visual inspection in genetic E200K CJD patients. A decreased trend was found on gray matter volume (uncorrected p<0.0001) and metabolism (FWE corrected) of the thalamus in genetic E200K patients.Conclusion: The clinical and image characteristics of genetic E200K CJD mimic fatal familial insomnia, manifested as a thalamic‐insomnia phenotype, indicating some specific underlying pathological changes might exist in E200K mutations. PET measurement is a sensitive approach to help identify the functional changes of the thalamus in prion disease.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Open AccessThalamic‐insomnia phenotype in genetic E200K Creutzfeldt‐Jakob disease: A PET/MRI study
Background: Insomnia and thalamic involvement are hallmarks of fatal familial insomnia; however, it was occasionally reported that genetic E200K Creutzfeldt‐Jakob disease (CJD) patients had also manifested thalamic‐insomnia phenotype. The study aimed to explore the clinical and neuroimage characteristics of genetic E200K CJD by comprehensive neuroimage analysis.Methods: Six genetic CJD patients carried Glu to Lys change at codon 200 (E200K) mutations on prion protein gene (PRNP), thirteen sporadic CJD (sCJD), and twenty‐two age‐ and sex‐matched normal controls were enrolled in the study. All participants completed hybrid positron emission tomography/ magnetic resonance imaging (PET/MRI) examinations. The high signal was visually inspected on diffusion weighted imaging (DWI) sequence. 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and structural images were quantitively analyzed by statistically parameter mapping (SPM). Clinical and image characteristics are compared between genetic E200K CJD patients and sporadic CJD patients.Results: There was no group difference in age (49.0±7.1 versus 55.0±4.9 versus 52.7±7.3, p = 0.193) and gender (3/3 versus 4/9 versus 11/11, p = 0.513) between genetic E200K CJD, sCJD, and normal controls. Insomnia was the main complaint in the genetic E200K CJD patients’ group (4/2 versus 1/12, p = 0.007). Hyperintensity, hypometabolism but not predominant atrophy of the thalamus was found by visual inspection in genetic E200K CJD patients. A decreased trend was found on gray matter volume (uncorrected p<0.0001) and metabolism (FWE corrected) of the thalamus in genetic E200K patients.Conclusion: The clinical and image characteristics of genetic E200K CJD mimic fatal familial insomnia, manifested as a thalamic‐insomnia phenotype, indicating some specific underlying pathological changes might exist in E200K mutations. PET measurement is a sensitive approach to help identify the functional changes of the thalamus in prion disease.
- Open Access
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Specific structuro‐metabolic pattern of thalamic subnuclei in fatal familial insomnia: A PET/MRI imaging study
Background: Dysfunction of the thalamus has been proposed as a core mechanism of fatal familial insomnia. However, detailed metabolic and structural alterations in thalamic subnuclei are not well documented. We aimed to address the multimodal structuro‐metabolic pattern at the level of the thalamic nuclei in fatal familial insomnia patients, and investigated the clinical presentation of primary thalamic alterations.Method: Five fatal familial insomnia patients and 10 healthy controls were enrolled in this study. All participants underwent neuropsychological assessments, polysomnography, electroencephalogram, and cerebrospinal fluid tests. MRI and fluorodeoxyglucose PET were acquired on a hybrid PET/MRI system. Structural and metabolic changes were compared using voxel‐based morphometry analyses and standardized uptake value ratio analyses, focusing on thalamic subnuclei region of interest analyses. Correlation analysis was conducted between gray matter volume and metabolic decrease ratios, and clinical features.Result: The whole‐brain analysis showed that gray matter volume decline was confined to the bilateral thalamus and right middle temporal pole in fatal familial insomnia patients, whereas hypometabolism was observed in the bilateral thalamus, basal ganglia, and widespread cortices, mainly in the forebrain. In the regions of interest analysis, gray matter volume and metabolism decreases were prominent in bilateral medial dorsal nuclei, anterior nuclei, and the pulvinar, which is consistent with neuropathological and clinical findings. A positive correlation was found between gray matter volume and metabolic decrease ratios.Conclusion: Our study revealed specific structuro‐metabolic pattern of fatal familial insomnia that demonstrated the essential roles of medial dorsal nuclei, anterior nuclei, and pulvinar, which may be a potential biomarker in diagnosis. Also, primary thalamic subnuclei alterations may be correlated with insomnia, neuropsychiatric, and autonomic symptoms sparing primary cortical involvement.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S3)
Open AccessSpecific structuro‐metabolic pattern of thalamic subnuclei in fatal familial insomnia: A PET/MRI imaging study
Background: Dysfunction of the thalamus has been proposed as a core mechanism of fatal familial insomnia. However, detailed metabolic and structural alterations in thalamic subnuclei are not well documented. We aimed to address the multimodal structuro‐metabolic pattern at the level of the thalamic nuclei in fatal familial insomnia patients, and investigated the clinical presentation of primary thalamic alterations.Method: Five fatal familial insomnia patients and 10 healthy controls were enrolled in this study. All participants underwent neuropsychological assessments, polysomnography, electroencephalogram, and cerebrospinal fluid tests. MRI and fluorodeoxyglucose PET were acquired on a hybrid PET/MRI system. Structural and metabolic changes were compared using voxel‐based morphometry analyses and standardized uptake value ratio analyses, focusing on thalamic subnuclei region of interest analyses. Correlation analysis was conducted between gray matter volume and metabolic decrease ratios, and clinical features.Result: The whole‐brain analysis showed that gray matter volume decline was confined to the bilateral thalamus and right middle temporal pole in fatal familial insomnia patients, whereas hypometabolism was observed in the bilateral thalamus, basal ganglia, and widespread cortices, mainly in the forebrain. In the regions of interest analysis, gray matter volume and metabolism decreases were prominent in bilateral medial dorsal nuclei, anterior nuclei, and the pulvinar, which is consistent with neuropathological and clinical findings. A positive correlation was found between gray matter volume and metabolic decrease ratios.Conclusion: Our study revealed specific structuro‐metabolic pattern of fatal familial insomnia that demonstrated the essential roles of medial dorsal nuclei, anterior nuclei, and pulvinar, which may be a potential biomarker in diagnosis. Also, primary thalamic subnuclei alterations may be correlated with insomnia, neuropsychiatric, and autonomic symptoms sparing primary cortical involvement.